

PHARMACY FORMULARY UPDATES EFFECTIVE 9/1/2016

MVP Health Care's Pharmacy & Therapeutics (P&T) Committee has determined that the following drugs, which have been recently approved by the FDA, will require **prior authorization** for at least the first six months following the date they are available on the market. The most current versions of our Formularies and Prior Authorization forms are available at www.mvphealthcare.com. MVP Formularies are also available from E-pocrates at www.epocrates.com

New Drugs (prior authorization required)

Drug Name	Indication	Commercial & Marketplace Tier	Medicare Part D Tier	MVP Medicaid
Cabometyx	RCC with prior antiangiogenic therapy	3	5	Non-formulary
Nuplazid	Hallucinations and delusions due to Parkinson's	3	5	Non-formulary
Briviact	Partial-onset seizures	3	5	Non-formulary
Tecentriq	Urothelila carcinoma	Medical	5	Medical
Orfadin	Hereditary tyrosinemia type 1	3	Non-formulary	Non-formulary
Ocaliva	Primary cholangitis	3	Non-formulary	Non-formulary
Onzetra	Migraines	3	Non-formulary	Non-formulary
Xtampza ER	Pain	3	Non-formulary	Non-formulary
Cetylev	Acetaminophen overdose	3	Non-formulary	Non-formulary
Probuphine	Opioid dependence	Medical	Non-formulary	Medical

For Commercial & Exchange (non-Medicare) business:

Formulary additions/changes

Drug Name	Tier	Drug Name	Tier
rosuvastatin	1(Tier 2 Exchange)	dofetilide	1(Tier 2 Exchange)
miglitol	1(Tier 2 Exchange)	armodafinil	1(Tier 2 Exchange)

Drugs removed from PA for Commercial & Exchange business:

Paxbind-M	Genvoya	Belbuca-QL	Veltassa	Tresiba
Onivyde-M	Imlygic-M	Cotellic	Ninlaro	
Yondelis-M	Gleostine	Tagrisso	Empliciti-M	

*May be covered under Part B if administered in the office or outpatient setting.

M- medical benefit

+ Step Therapy QL-Quantity Limits apply

ALERT: SYSTEM MAINTENANCE SEPTEMBER 24 –25, 2016

MVP Health Care® is upgrading to a new version of its core operations platform (Facets). As a result of the needed upgrade, the system, as well as account features and functions on the MVP website, may be limited or unavailable beginning 5 am on Saturday, September 24 through 12 pm on Sunday, September 25.

We apologize for the disruption.

If you have any questions with respect to this notice, please contact your Professional Relations Representative.

